| I am very happy to announce that within the recently completed capital raise of atai Life Sciences (Nasdaq: ATAI) of a total of USD 63.25 million (in gross proceeds, including full exercise of the “greenshoe”, less costs), my family office, Apeiron Investment Group, has invested USD 22.75 million, which equals approximately 36% of the total offering.
With this step, as reported in Form 4 Apeiron has increased its stake in atai from 33,885,999 shares to 44,721,717 shares, increasing Apeiron’s ownership stake from 19.9% to 22.3%.
Click here for news about completion of the offering.
I personally believe that psychedelic medicines will be a game-changer for mental health issues, and that the next two years will be decisive for the industry, and especially for atai as a (if not, the) leader in the space.
The most comprehensive overview is still my blog post from last year.
Here are some reasons why I chose to increase my stake now:
As always, publicly available information only, and this represents my personal view as founder and largest shareholder of atai:
- As reported by atai, the capital increase extends runway into 2027
- J&J’s Spravato (Esketamine) – which takes approximately two hours to apply – has become a blockbuster drug according to figures released by J&J.
Esketamine IMHO is like a “semi-psychedelic” in that it is weaker but gives us a preview of the potential power of “real” psychedelics.
While it had a slow start, Spravato sales are really picking up… |
